The Suzlon Case: Why Financial Transparency Remains a Boardroom Responsibility
Introduction
A company's balance sheet is supposed to tell a story people can trust. When that story turns out to be incomplete — or worse, deliberately shaped to look better than it was — the fallout rarely stays contained to the finance team.
That's roughly what's playing out with Suzlon Energy right now. A regulatory order has revisited years of the company's financial statements, flagged a set of intra-group transactions and accounting choices and imposed penalties running into crores — not just on the company, but on its promoters and former finance officials personally. Suzlon has pushed back and taken the matter to appeal, so the final word on this is still to come.
We're not writing this to relitigate the case. What interests us is the governance question sitting underneath it: how does something like this get past a board in the first place? Financial transparency is often treated as an accounting exercise — something the CFO signs off on and the auditor certifies. But the Suzlon case is a useful reminder that transparency has always been, first and foremost, a boardroom responsibility.
Inside the Suzlon Order: A Quick Recap
Here's what the order actually says, stripped of the legal language.
The case goes back to financial statements Suzlon filed between FY2014 and FY2018. According to the regulator, a few internal transactions during this period painted a rosier picture of the company's financial health than was actually warranted.
The biggest piece of it involves an internal restructuring. Suzlon transferred its operations and maintenance business to a wholly-owned subsidiary, Suzlon Global Services, for around ₹2,000 crore — and booked a gain of close to ₹1,923 crore on that transfer. Then, shares of that same subsidiary were transferred again, this time to another group entity, generating a further gain of roughly ₹830 crore. On paper, these were real transactions. But they were happening within the group — the company was essentially moving assets between its own entities and recognising profit each time it did.
There's a second thread to the case too. Suzlon had an exposure of about ₹4,050 crore under a Standby Letter of Credit. For a while, this was disclosed the way you'd expect — as a contingent liability. But from FY2017-18 onward, that disclosure stopped, after the company began treating the exposure as an insurance contract instead. A large financial exposure, in other words, seemingly moved off the radar of anyone reading the balance sheet.
Taken together, the regulator's view was that these choices didn't give investors a fair picture of where the company actually stood. The order imposed penalties of roughly ₹28.95 crore in total — around ₹16 crore on Suzlon itself, with the rest split across its promoters and two former CFOs.
It's worth being fair to where things stand right now, though. This order actually overturned an earlier ruling from 2025 that had cleared Suzlon and its promoters of any wrongdoing on the same facts. Suzlon has said it will contest the new order and the appellate tribunal has already stayed its operation, subject to a partial deposit. So this is very much a live matter — not a closed case. We're using it here purely as a lens into a governance pattern, not as a verdict on anyone involved.
This Isn't Really About One Company
If Suzlon were an isolated case, this would just be one company's legal battle. It isn't.
Over the past couple of years, we've seen a fairly consistent pattern show up across Indian companies of different sizes and sectors — misstated financials, undisclosed related-party dealings, subsidiaries quietly excluded from consolidation, exposures that stop being disclosed the moment they become inconvenient. The specific mechanics differ each time, but the underlying story tends to rhyme.
Take a company like Man Industries, where a subsidiary was reportedly excluded from consolidated financials for several years without explanation — a move regulators said suppressed group-level losses while inflating the parent company's profits on paper. Or cases where funds were allegedly routed through related entities under the guise of ordinary business transactions, only surfacing years later once someone finally traced where the money actually went.
What connects these cases isn't fraud sophistication. It's usually something far more mundane: a board that either didn't look closely enough, or looked and didn't push back hard enough.
That's really the point we want to make here. Regulators are increasingly signalling that financial transparency issues aren't freak accidents caused by one rogue executive. They're symptomatic of a boardroom that wasn't asking the right questions at the right time — about related-party transactions, about internal restructuring, about exposures that quietly move on and off the balance sheet.
Suzlon just happens to be the case in the headlines this year. The pattern it sits inside is bigger than one company and that's exactly why it's worth every board paying attention to — regardless of sector, regardless of size.
The Grey Zones Where Boards Tend to Look Away
Most financial transparency failures don't happen through a single dramatic act of fraud. They happen quietly, in the grey zones — areas complex enough that boards often assume "the auditors will catch it" and move on. The Suzlon case sits almost entirely in these zones.
Here are the areas where we consistently see boards under-scrutinise the numbers in front of them:
1. Intra-group and related-party transactions When a company transfers assets, businesses, or shares between its own entities, the transaction is easy to wave through — after all, it's "internal." But these are exactly the deals that can be used to recognise gains on paper without any real cash or value entering the business from outside. Boards often treat related-party approvals as a formality rather than a checkpoint that deserves real interrogation.
2. Complex accounting treatments Reclassifying an exposure — say, from a contingent liability to something like an insurance contract — can be a legitimate accounting call. Or it can be a way of making a large risk disappear from the disclosures. The line between the two isn't always obvious to a board reading a summarised memo, which is precisely why it needs more scrutiny, not less.
3. Gains from internal restructuring When a company reports a large one-time gain from selling an asset to its own subsidiary, that number can inflate profitability in a way that has little to do with actual business performance. Boards need to ask a simple question every time this happens: does this gain represent real economic value, or just a number created by moving assets around?
4. Sudden changes in disclosure treatment One of the clearest warning signs in the Suzlon case was a disclosure that simply stopped appearing after a certain year. Any time a company changes how — or whether — it discloses a material exposure, that change itself deserves a direct explanation to the board, not just a footnote in the financials.
Why do these grey zones keep slipping through? Because they sit exactly at the edge of what a non-finance board member feels confident challenging. The transactions are technically compliant, backed by accounting rationale and signed off by auditors. Pushing back requires a director who understands the mechanics well enough to ask, "why this treatment and why now?" — and who's willing to keep asking until the answer actually makes sense.
Transparency Was Never Just the CFO's Job
There's a comfortable assumption that runs through a lot of boardrooms: financial transparency is the CFO's responsibility, the auditor's job to verify and the board's job to simply approve once both have signed off. The Suzlon case is a fairly direct challenge to that assumption.
Here's why that division of responsibility doesn't hold up.
The audit committee exists precisely for moments like this. Its job isn't to re-do the CFO's work or second-guess every line item. It's to ask the uncomfortable question when something looks unusual — a large internal gain, a disclosure that quietly disappears, an exposure reclassified without much explanation. When cases like this come to light, "the audit committee reviewed and approved it" is often part of the very same finding that goes against the company, not a defence that shields it.
"We relied on management's representation" is wearing thin as a governance defence. It's true that boards can't independently verify every transaction — that's not realistic and nobody expects it. But there's a meaningful difference between relying on management's information and relying on it without ever stress-testing it. Regulators are increasingly drawing that distinction too and it's showing up in how personally promoters and CFOs are being held accountable — not just the company as an entity.
Fiduciary duty doesn't pause at the edge of complexity. A director's responsibility to shareholders doesn't reduce just because a transaction is technical or hard to follow. If anything, the more complex a structure gets — subsidiaries transacting with subsidiaries, gains recognised through internal transfers — the more it demands board-level scrutiny, not less. Complexity is often exactly where problems hide, precisely because it discourages people from asking basic questions.
Independent directors carry a specific weight here. They're on the board precisely to bring outside judgment to situations like this. When the numbers look unusually strong, or a disclosure quietly vanishes, an independent director asking "walk me through why" is doing exactly the job they were appointed for.
The larger point is simple: transparency isn't produced by one function and inspected by another. It's a collective outcome of how seriously the entire board treats its oversight role — and that responsibility doesn't transfer away just because the accounting gets complicated.
The Red Flags Every Independent Director Should Know
Reading a balance sheet is one thing. Knowing which specific patterns deserve a closer look is another — and that's usually the gap between a board that catches problems early and one that finds out from a regulatory order.
Based on cases like Suzlon's, here are the red flags worth watching for:
Red Flag | What It Often Signals |
Large gains from intra-group transfers | Profit recognised without new external value entering the business |
A disclosure that quietly stops appearing | A material exposure being pushed out of investor view |
Reclassification of a liability or exposure | Possible use of accounting flexibility to reduce visible risk |
Related-party transactions approved with minimal discussion | Weak scrutiny at the exact point where scrutiny matters most |
Profit growth outpacing operating cash flow | Paper profits that may not reflect real business performance |
Frequent restructuring between subsidiaries | Complexity that can obscure where value — and risk — actually sits |
None of these, on their own, automatically means something is wrong. Businesses restructure for legitimate reasons all the time and accounting treatments do genuinely change with new standards or circumstances. The point isn't suspicion by default — it's discipline by default.
What should a director actually do when one of these shows up?
Ask for the transaction to be explained in plain language, not just accounting terms — if it can't be explained simply, that's itself worth noting.
Ask why now — timing changes around disclosure or classification are rarely coincidental.
Ask what the transaction would look like if presented to an outside investor with no context — would it still look routine?
Request a direct conversation with the auditor, without management in the room, if something still doesn't sit right.
The directors who catch issues early aren't necessarily the most technically expert people in the room. They're usually just the ones who keep asking "why" until the answer genuinely makes sense — instead of stopping once it sounds plausible.
A Harder Lesson for Promoters and Family-Run Businesses
One detail in the Suzlon case is easy to miss if you're only skimming the headlines: the penalties weren't only on the company. They were personally imposed on the promoters and former CFOs named in the order.
That distinction matters enormously for promoter-led and family-run businesses and it's worth sitting with.
The company and the promoter are not the same shield anymore. There was a time when regulatory action largely stopped at the corporate entity — a fine on the company, a reputational dent and business continued. That's shifting. When financial statements are found to be misleading, the individuals who signed off, approved, or should reasonably have questioned those numbers are increasingly being named and penalised directly. For a promoter, that's a far more personal stake than a corporate fine ever was.
Family businesses often blur the line between "founder judgment" and "board oversight." In many promoter-led companies, board approval can end up being a formality when the promoter is also driving the strategy, the numbers and the narrative. That closeness is often what makes the business move fast — but it's also exactly what removes the natural friction that catches problems early. A board that rarely disagrees with its promoter isn't really providing oversight; it's providing a rubber stamp.
Reputational cost outlasts the legal outcome. Regardless of how the Suzlon appeal eventually plays out, the association between the company's name and "misleading financial statements" has already been made — in investor conversations, in media coverage, in how lenders and partners perceive the business going forward. That kind of reputational cost doesn't reverse itself just because a tribunal rules in the company's favour later.
What should promoters take away from this? Not defensiveness — the opposite. The businesses that hold up best over time tend to be the ones where promoters actively invite scrutiny from their boards, rather than treating independent oversight as a regulatory box to tick. An engaged, questioning board isn't a threat to a promoter's legacy. In cases like this, it's often the only thing standing between a promoter and a very personal, very public consequence.
Building Boards That Actually Catch This Early
Knowing the red flags is one thing. Acting on them consistently is another. A few practical shifts help:
1. Give the audit committee real teeth. Frequent, detailed reviews — not quarterly rubber stamps.
2. Use independent forensic reviews, not just statutory audits, especially around related-party deals and restructuring.
3. Scrutinise related-party transactions — would this deal make sense if the counterparty weren't part of the group?
4. Build financial literacy across non-finance directors, so sharp questions become second nature.
5. Give auditors a direct line to the board, without management in the room.
None of this is expensive to set up. It just requires treating financial oversight as ongoing — not a formality that ends once the numbers are approved.
The Regulatory Lens Is Only Getting Sharper
One detail in the Suzlon case says a lot about where things are headed: this order came after an earlier ruling had already cleared the company on the same facts. Regulators are increasingly willing to revisit and reopen matters they'd previously closed — which means "cleared once" is no longer the same as "settled forever."
A few shifts we expect to see more of:
Personal accountability is rising. Promoters and CFOs are increasingly named individually, not just the company.
Old cases aren't necessarily closed cases. Regulators are using revisionary powers more actively to revisit past findings.
Complex structures are drawing more scrutiny, not less. Intra-group transactions and internal restructuring are becoming default areas of regulatory interest.
Boards are the new accountability layer. Enforcement is increasingly asking not just "were the numbers wrong," but "did the board have a real chance to catch this."
The message for boards is straightforward: the standard for what counts as adequate oversight is only going to get higher from here.
Quick FAQs
What is the Suzlon case about?
A regulatory order found Suzlon's FY14–FY18 financial statements potentially misleading, tied to intra-group transactions and a reclassified liability. Suzlon is appealing.
Why does this matter for boards generally?
It shows how easily complex, technically-compliant transactions can bypass real board scrutiny.
Is financial transparency only the CFO's job
No — it's a shared board responsibility, especially for audit committees and independent directors.
Closing Thoughts
The Suzlon case is still unfolding, but the governance lesson is already clear: transparency isn't guaranteed by compliance alone — it requires boards that actively question, not just approve. That vigilance is what protects a company long before any regulator has to step in.
Strengthen Your Boardroom Expertise with Directors’ Institute
Effective corporate governance begins with informed, accountable and proactive board leadership. Understanding financial transparency, audit oversight and fiduciary responsibilities is essential for every director navigating today's evolving regulatory environment.
Explore professional learning and certification opportunities with Directors’ Institute to strengthen your boardroom knowledge and governance expertise.
Comments